Experience

• Over the course of his career, Mr. Bonnes has represented clients on a variety of significant transactions. Some of his experience includes representing:

  • Acacia Communications in its acquisition by Cisco Systems for $4.5 billion in cash and assumed equity awards
  • Akouos in its acquisition by Eli Lilly and Company for up to $610 million 
  • Alcon in the merger resulting in sale of its outstanding public shares to Novartis for approximately $12.9 billion
  • American Science and Engineering in its acquisition by OSI Systems for $269 million
  • Analogic Corporation in its acquisition by an affiliate of Altaris Capital Partners for $1.1 billion
  • Arch Chemicals in its sale to the Lonza Group for approximately $1.4 billion
  • Barton Associates in its sale to H.I.G. Capital
  • Casella Waste Systems in its acquisition of the assets of Youngblood Disposal Enterprises of Western New York
  • Cynosure in its acquisition by Hologic for $1.65 billion
  • Editas Medicine in multiple transactions including:
    • its acquisition of i2 Pharmaceuticals’ assets and capabilities for guide RNA engineering and manufacturing
    • the sale of its iNK cell franchise and licensing of certain gene editing technologies to Shoreline Biosciences
  • Endurance International Group in multiple transactions including:
    • its acquisition by Clearlake Capital Group for $3 billion
    • its acquisition of Retention Science
    • the sale of its SinglePlatform digital storefront business to TripAdvisor
    • the purchase of its largest co-located data center from ACE Data Centers and Ace Holdings
    • its acquisition of the Verio hosting business of NTT America
    • its acquisition of the BuyDomains business of NameMedia
    • its acquisition of Typepad LLC
    • its acquisition of the Directi web presence business from Directi Web Technologies Holdings

  • Entegris, Inc. in its acquisition of Digital Specialty Chemicals Limited
  • EverQuote in multiple transactions including: 
    • its acquisition of Crosspointe Insurance & Financial Services
    • its acquisition of PolicyFuel
    • the sale of assets relating to its health insurance vertical to MyPlanAdvocate Insurance Solutions
  • General Catalyst in multiple transactions including:
    • the $18.5 billion merger of its portfolio company Livongo with Teladoc Health
    • the $1.125 billion sale of its portfolio company Clarabridge
    • the sale of its portfolio company ClassPass to Mindbody in a stock-for-stock merger, as well as a strategic investment of $500 million in the combined company in conjunction with the acquisition  
    • the sale of its portfolio company Digit to Oportun Financial for approximately $212.9 million
    • the combination of its portfolio companies Commure and Athelas
    • the sale of its portfolio company Armorblox to Cisco Systems
    • the sale of its portfolio company Cadre to Yieldstreet
    • the sale of its portfolio company 6D.ai to Niantic
    • the growth investment in its portfolio company Photoshelter by Clearhaven Partners
    • the sale of its portfolio company Stellar Aurora (creator of the messaging platform Quill) to Twitter
    • the growth investment in its portfolio company Yottaa by PSG 
  • Genpact Limited in connection with a $1 billion equity investment by Bain Capital
  • Health Monitor Network in a significant growth capital investment by private equity firm WestView Capital Partners
  • Hydra Biosciences in the sale of its pre-clinical pain program to Eli Lilly and Company
  • IBM in the sale of its global retail store solutions business to Toshiba Tec for approximately $850 million
  • Jebbit in its $70 million strategic growth investment by Vista Equity Partners
  • Kadant in its acquisition of Syntron Material Handling Group
  • Karyopharm Therapeutics in the sale of its investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative condition to Biogen
  • KBR, Inc. in its spin-off of its Mission Technology Solutions (MTS) segment.
  • Klinge Corporation in its sale to Trane Technologies
  • The Board of Directors of Par Pharmaceutical Companies in its sale to TPG Capital for $1.9 billion
  • Progress in multiple transactions including:
    • its acquisition of Kemp for $258 million 
    • its acquisition of Chef for $220 million 
    • its acquisition of Ipswitch for $225 million
  • QD Vision in the sale of quantum dot related intellectual property to Samsung 
  • Regal Entertainment Group in its acquisition by Cineworld Group for $5.9 billion, including the assumption of debt and net of cash acquired
  • Revvity (formerly known as PerkinElmer) in multiple transactions including:
    • in its acquisition of BioLegend for $5.25 billion
    • the sale of its Applied, Food and Enterprise Services businesses to New Mountain Capital for $2.45 billion
  • Samsara BioCapital in its acquisition of Respira Therapeutics, Inc. 
  • Sonus Networks in multiple transactions including:
    • its acquisition of Taqua
    • its acquisition of the SDN technology assets of Treq Labs 
  • Stackdriver in its acquisition by Google
  • Staples in its attempted acquisition of Office Depot for $6.3 billion (terminated) and its acquisition by Sycamore Partners for $6.9 billion
  • Starbucks in its acquisition of Teavana for approximately $620 million 
  • Takeda Pharmaceutical Company, through its wholly-owned subsidiary Millennium Pharmaceuticals, in a five-year collaboration with Maverick Therapeutics
  • Telix Pharmaceuticals Limited in its pending acquisition of RLS for $230 million and up to $20 million in contingent consideration
  • Thermo Fisher Scientific in multiple transactions including:
    • its acquisition of Solventum’s purification and filtration business for approximately $4.1 billion
    • its acquisition of Gatan, a wholly owned subsidiary of Roper, for approximately $925 million
  • Vail Resorts in its acquisition of Peak Resorts, the owner of 17 ski resorts in the Northeastern, Mid-Atlantic and Midwestern United States, for $264 million
  • Veveo in its acquisition by Rovi Corporation 
  • Viamet Pharmaceuticals in its sale to NovaQuest Capital Management
  • WEX in several transactions including:
    • its acquisition of Payzer for $250 million
    • its acquisition of benefitexpress for $275 million
    • its acquisition of Discovery Benefits for $425 million
    • its acquisition of Noventis for $310 million
    • the acquisition of certain health savings account assets from the HealthcareBank division of Bell Bank for $250 million and up to $225 million in contingent consideration 
    • a $400 million dollar PIPE investment from an affiliate of Warburg Pincus 
    • its acquisition of Electronic Funds Source for $1.1 billion in cash and 4.0 million shares of its common stock
    • its acquisition of eNett International (Jersey) Limited and Optal Limited for $578 million
  • Xpress Natural Gas in its sale to Basalt Infrastructure Partners